Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: The state of the art

Jemal, 2009, Cancer statistics, 2009, CA Cancer J Clin, 59, 225, 10.3322/caac.20006 Melamed, 1964, Natural history and clinical behavior of in situ carcinoma of the human urinary bladder, Cancer, 17, 1533, 10.1002/1097-0142(196412)17:12<1533::AID-CNCR2820171205>3.0.CO;2-7 Melicow, 1952, Histological study of vesical urothelium intervening between gross neoplasms in total cytectomy, J Urol, 68, 261, 10.1016/S0022-5347(17)68193-X Cheng, 1999, Survival of patients with carcinoma in situ of the urinary bladder, Cancer, 85, 2469, 10.1002/(SICI)1097-0142(19990601)85:11<2469::AID-CNCR24>3.0.CO;2-U Stenzl, 2008, Can we still afford bladder cancer?, Curr Opin Urol, 18, 488, 10.1097/MOU.0b013e32830b8925 Edge, 2010 Hodges KB, Lopez-Beltran A, Davidson DD, Montironi R, Cheng L. Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum Pathol; in press. Cheng, 2008, Neoplasms of the urinary bladder, 259 Melicow, 1952, Intra-urothelial cancer: carcinoma in situ, Bowens's disease of the urinary system: discussion of thirty cases, J Urol, 68, 763, 10.1016/S0022-5347(17)68279-X Lopez-Beltran, 2002, Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation, Virchows Arch, 440, 3, 10.1007/s00428-001-0577-6 Takenaka, 2008, Clinical outcomes of Bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder, Int J Urol, 15, 309, 10.1111/j.1442-2042.2008.02012.x Johansson, 1997, Epidemiology and etiology of bladder cancer, Semin Surg Oncol, 13, 291, 10.1002/(SICI)1098-2388(199709/10)13:5<291::AID-SSU2>3.0.CO;2-8 Zeegers, 2004, The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review, World J Urol, 21, 392, 10.1007/s00345-003-0382-8 Demir, 2003, Cytopathological expression of different types of urothelial carcinoma in situ in urinary bladder washings, BJU Int, 92, 906, 10.1111/j.1464-410X.2003.04523.x Fernando, 2007, Importance of red patches diagnosed in cystoscopy for haematuria and lower urinary tract symptoms, Postgrad Med J, 83, 62, 10.1136/pgmj.2006.050112 Garbar, 2007, Is urinary tract cytology still useful for diagnosis of bladder carcinomas? A large series of 592 bladder washings using a five-category classification of different cytological diagnoses, Cytopathology, 18, 79, 10.1111/j.1365-2303.2007.00426.x Shariat, 2007, Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy, Eur Urol, 51, 152, 10.1016/j.eururo.2006.08.037 Shariat, 2006, Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy, Urology, 68, 538, 10.1016/j.urology.2006.03.033 Vineis, 1988, Effects of timing and type of tobacco in cigarette-induced bladder cancer, Cancer Res, 48, 3849 Fleshner, 1999, Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder, Cancer, 86, 2337, 10.1002/(SICI)1097-0142(19991201)86:11<2337::AID-CNCR23>3.0.CO;2-6 Reulen, 2008, A meta-analysis on the association between bladder cancer and occupation, Scand J Urol Nephrol Suppl, 64, 10.1080/03008880802325192 Castelao, 2000, Non-steroidal anti-inflammatory drugs and bladder cancer prevention, Br J Cancer, 82, 1364, 10.1054/bjoc.1999.1106 Genkinger, 2007, Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow-up study, Int J Cancer, 120, 2221, 10.1002/ijc.22546 Abol-Enein, 2008, Infection: is it a cause of bladder cancer?, Scand J Urol Nephrol Suppl, 79, 10.1080/03008880802325309 Cheng, 2000, Flat intraepithelial lesions of the urinary bladder, Cancer, 88, 625, 10.1002/(SICI)1097-0142(20000201)88:3<625::AID-CNCR20>3.0.CO;2-A Hudson, 1995, Carcinoma in situ of the bladder, J Urol, 153, 564, 10.1016/S0022-5347(01)67650-X Lopez-Beltran, 2002, The pagetoid variant of bladder urothelial carcinoma in situ: a clinicopathological study of 11 cases, Virchows Arch, 441, 148, 10.1007/s00428-002-0627-8 Swinn, 2004, Biopsy of the red patch at cystoscopy: is it worthwhile?, Eur Urol, 45, 471, 10.1016/j.eururo.2003.11.019 Cauberg, 2009, A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications, Eur Urol, 56, 287, 10.1016/j.eururo.2009.02.033 Fradet, 2007, A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study, J Urol, 178, 68, 10.1016/j.juro.2007.03.028 Colombo, 2007, Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder, Ther Clin Risk Manage, 3, 1003 Levi, 2001, Clinical significance of denuded urothelium in bladder biopsy, J Urol, 166, 457, 10.1016/S0022-5347(05)65963-0 van Oers, 2006, Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder, Int J Cancer, 119, 1212, 10.1002/ijc.21958 McKenney, 2001, Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion, Am J Surg Pathol, 25, 356, 10.1097/00000478-200103000-00010 Chan, 2001, In situ adenocarcinoma of the bladder, Am J Surg Pathol, 25, 892, 10.1097/00000478-200107000-00007 Cheng, 1999, Natural history of urothelial dysplasia of the bladder, Am J Surg Pathol, 23, 443, 10.1097/00000478-199904000-00009 Lopez-Beltran, 2002, Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer, J Clin Pathol, 55, 641, 10.1136/jcp.55.9.641 McKenney, 2001, Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens, Am J Surg Pathol, 25, 1074, 10.1097/00000478-200108000-00013 Mallofre, 2003, Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia, Mod Pathol, 16, 187, 10.1097/01.MP.0000056628.38714.5D Schrier, 2006, The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma, Eur Urol, 50, 76, 10.1016/j.eururo.2005.12.041 Ick, 1997, Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after Bacillus Calmette-Guerin treatment, Urology, 49, 541, 10.1016/S0090-4295(96)00624-3 Ecke, 2008, TP53 gene mutations as an independent marker for urinary bladder cancer progression, Int J Mol Med, 21, 655 Salinas-Sanchez, 2008, Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study, Urol Oncol, 26, 620, 10.1016/j.urolonc.2007.07.011 Gonzalez, 2008, Prognostic value of combined p53 and survivin in pT1G3 urothelial carcinoma of the bladder, Am J Clin Pathol, 129, 232, 10.1309/2TY6GTV1GQ6B5ARM Shariat, 2003, Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder, Urology, 61, 1140, 10.1016/S0090-4295(03)00236-X Shariat, 2001, E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder, Urology, 57, 60, 10.1016/S0090-4295(00)00892-X Sun, 2002, E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma, Hum Pathol, 33, 996, 10.1053/hupa.2002.127441 Spruck, 1994, Two molecular pathways to transitional cell carcinoma of the bladder, Cancer Res, 54, 784 Cheng, 2009, Molecular determinants of tumor recurrence in the urinary bladder, Future Oncol, 5, 843, 10.2217/fon.09.50 Hartmann, 2002, Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder, Cancer Res, 62, 809 Hopman, 2002, Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma, Am J Pathol, 161, 1119, 10.1016/S0002-9440(10)64388-X Zieger, 2009, Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development, Int J Cancer, 125, 2095, 10.1002/ijc.24619 Dyrskjot, 2004, Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification, Cancer Res, 64, 4040, 10.1158/0008-5472.CAN-03-3620 Dyrskjot, 2007, Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study, Clin Cancer Res, 13, 3545, 10.1158/1078-0432.CCR-06-2940 Budman, 2008, Biomarkers for detection and surveillance of bladder cancer, Can Urol Assoc J, 2, 212, 10.5489/cuaj.600 Alvarez, 2007, Bladder cancer biomarkers: current developments and future implementation, Curr Opin Urol, 17, 341, 10.1097/MOU.0b013e3282c8c72b Munro, 2006, Urinary biomarker profiling in transitional cell carcinoma, Int J Cancer, 119, 2642, 10.1002/ijc.22238 Sanchez-Carbayo, 2006, Profiling bladder cancer using targeted antibody arrays, Am J Pathol, 168, 93, 10.2353/ajpath.2006.050601 Lokeshwar, 2001, Current bladder tumor tests: does their projected utility fulfill clinical necessity?, J Urol, 165, 1067, 10.1016/S0022-5347(05)66428-2 Halling, 2002, A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine, J Urol, 167, 2001, 10.1016/S0022-5347(05)65072-0 Cohen, 2003, Clinical practice. Microscopic hematuria, N Engl J Med, 348, 2330, 10.1056/NEJMcp012694 Halling, 2000, A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma, J Urol, 164, 1768, 10.1016/S0022-5347(05)67104-2 Gudjonsson, 2008, The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer, Eur Urol, 54, 402, 10.1016/j.eururo.2007.11.051 Moonen, 2007, UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer, Eur Urol, 51, 1275, 10.1016/j.eururo.2006.10.044 Bubendorf, 2001, Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings, Am J Clin Pathol, 116, 79, 10.1309/K5P2-4Y8B-7L5A-FAA9 Sarosdy, 2002, Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer, J Urol, 168, 1950, 10.1016/S0022-5347(05)64270-X Schwarz, 2008, Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions, J Clin Pathol, 61, 272, 10.1136/jcp.2007.049684 Messing, 2005, Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States, J Urol, 174, 1238, 10.1097/01.ju.0000173918.84006.4d Schroeder, 2004, A side by side comparison of cytology and biomarkers for bladder cancer detection, J Urol, 172, 1123, 10.1097/01.ju.0000134347.14643.ab Tetu, 2009, Diagnosis of urothelial carcinoma from urine, Mod Pathol, 22, S53, 10.1038/modpathol.2008.193 Morales, 1976, Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors, J Urol, 116, 180, 10.1016/S0022-5347(17)58737-6 Lamm, 1991, A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guerin for transitional-cell carcinoma of the bladder, N Engl J Med, 325, 1205, 10.1056/NEJM199110243251703 Lamm, 1995, BCG in perspective: advances in the treatment of superficial bladder cancer, Eur Urol, 27, 2, 10.1159/000475201 Cookson, 1997, The treated natural history of high risk superficial bladder cancer: 15-year outcome, J Urol, 158, 62, 10.1097/00005392-199707000-00017 Talic, 1994, Intravesical Evans Bacille Calmette-Guerin for carcinoma in situ of the urinary bladder. Scottish Urological Oncology Group, Br J Urol, 73, 645, 10.1111/j.1464-410X.1994.tb07549.x Lamm, 2000, Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study, J Urol, 163, 1124, 10.1016/S0022-5347(05)67707-5 Palou, 2001, Control group and maintenance treatment with Bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors, J Urol, 165, 1488, 10.1016/S0022-5347(05)66333-1 Alfred Witjes, 2009, Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party, World J Urol, 27, 319, 10.1007/s00345-009-0384-2 Grossman, 2008, Bacillus Calmette-Guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer, Rev Urol, 10, 281 Utz, 1970, The plight of the patient with carcinoma in situ of the bladder, J Urol, 103, 160, 10.1016/S0022-5347(17)61913-X Van Gils-Gielen, 1995, Risk factors in carcinoma in situ of the urinary bladder, Urology, 45, 581, 10.1016/S0090-4295(99)80047-8 Sanderson, 2007, Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments, BJU Int, 100, 11, 10.1111/j.1464-410X.2007.06841.x Solsona, 1997, Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): its impact on management, Urology, 49, 347, 10.1016/S0090-4295(96)00571-7 Kenworthy, 1996, The risk of upper tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter, J Urol, 155, 501, 10.1016/S0022-5347(01)66433-4 Balaji, 1999, Upper tract recurrences following radical cystectomy: an analysis of prognostic factors, recurrence pattern and stage at presentation, J Urol, 162, 1603, 10.1016/S0022-5347(05)68176-1 Sanderson, 2007, Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup, J Urol, 177, 2088, 10.1016/j.juro.2007.01.133 Batista, 1994, Significance of urethral carcinoma in situ in specimens of cystectomy, Eur Urol, 25, 313, 10.1159/000475308 Raj, 2006, Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer, Cancer, 107, 2167, 10.1002/cncr.22238 Silver, 1997, Ureteral carcinoma in situ at radical cystectomy: does the margin matter?, J Urol, 158, 768, 10.1016/S0022-5347(01)64312-X Yuasa, 2006, Radical nephroureterectomy as initial treatment for carcinoma in situ of upper urinary tract, Urology, 68, 972, 10.1016/j.urology.2006.05.040 Patel SG, Cookson MS, Barocas DA, Clark PE, Smith JAJ, Chang SS. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. BJU Int; in press. Tobisu, 1997, Jpn J Clin Oncol, 27, 406, 10.1093/jjco/27.6.406